This is a permanent results page for your analyzed data. Please save the link in your browser's address bar.
| Title / Description | Imatinib treatment of chronic myeloid leukemia cell lines: KU-812, KCL-22 and JURL-MK1 |
| Accession | GDS4177 |
| Summary | Analysis of CML cell lines (KU-812, KCL-22, and JURL-MK1) treated with tyrosine kinase inhibitor imatinib. Imatinib inhibits oncogenic BCR-ABL1, a tyrosine kinase present in most CML patients. Results provide insight into molecular mechanisms underlying imatinib inhibition of CML. |
| Organism | Homo sapiens |
| Platform | GPL570 |
| Normalized | False |
| Parsed SOFT file |
| Differential expression method | Characteristic Direction |
| Cutoff | 500 |
| Cell | KU812, KCL-22, JURL-MK1 |
| Perturbation | Imatinib |
| Disease | Chronic myeloid leukemia |
| Principal Component Analysis | |
| Hierarchical clustering |
| Gene lists | Enrichr | L1000CDS2 | PAEA | |
| Up |
|
|||
| Down |
|
|||
| Combined |
|
|
|
